A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Suzuki, R [1 ]
Hasegawa, Y [1 ]
Baba, K [1 ]
Saka, H [1 ]
Saito, H [1 ]
Taniguchi, H [1 ]
Yamamoto, M [1 ]
Matsumoto, S [1 ]
Kato, K [1 ]
Shimokata, K [1 ]
机构：
[1] Cent Japan Lung Study Grp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：640S / 640S
页数：1
相关论文
共 50 条
  • [1] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [2] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    Suzuki, R.
    Hasegawa, Y.
    Baba, K.
    Saka, H.
    Saito, H.
    Taniguchi, H.
    Yamamoto, M.
    Matsumoto, S.
    Kato, K.
    Oishi, T.
    Imaizumi, K.
    Shimokata, K.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1599 - 1603
  • [3] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    R Suzuki
    Y Hasegawa
    K Baba
    H Saka
    H Saito
    H Taniguchi
    M Yamamoto
    S Matsumoto
    K Kato
    T Oishi
    K Imaizumi
    K Shimokata
    [J]. British Journal of Cancer, 2006, 94 : 1599 - 1603
  • [4] A PHASE II STUDY OF FIRST-LINE BORTEZOMIB (B) IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC)
    Planchard, D.
    Besse, B.
    Meric, J. B.
    Veillard, A. S.
    Pignon, J. P.
    Chan, K.
    Mathiot, C.
    Lumbroso, J.
    Lafontaine, C.
    Soria, J. C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 96 - 96
  • [5] First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer
    Lange, T
    Müller-Tidow, C
    Serve, H
    Hoffknecht, P
    Berdel, WE
    Thomas, M
    [J]. ONCOLOGY REPORTS, 2005, 14 (06) : 1539 - 1542
  • [6] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Saijo, N
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
  • [7] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian Shu Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing China
    [J]. Journal of Nanjing Medical University, 2009, 23 (06) : 392 - 397
  • [8] Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
    Yongmei Yin1
    [J]. The Journal of Biomedical Research, 2009, (06) : 392 - 397
  • [9] Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage II/IV non-small-cell lung cancer.
    Swinson, D
    Williams, S
    Beddard, K
    Price, L
    Reaper, L
    Cullen, MH
    Ferry, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 684S - 684S
  • [10] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
12345